{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:42:08Z","timestamp":1787643728150,"version":"build-2736575974"},"reference-count":54,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tomography"],"abstract":"<jats:p>Background\/Objectives: Liver metastases are common among patients with breast cancer and have a poor prognosis if left untreated. The aim of this systematic review is to evaluate and compare chemoembolization (TACE) versus radioembolization (TARE) treatments in patients with breast cancer liver-dominant metastases in terms of overall survival (OS), local tumor control (LC), and toxicity. Methods: The S.P.I.D.E.R framework was used to address the clinical question. A systematic literature search using PubMed and Scopus was performed to identify full articles evaluating the efficacy of TACE and TARE in patients with liver metastases from breast cancer. Results: The literature search resulted in 10 articles for TACE, 13 articles for TARE and 1 for combined TACE\/TARE, totaling 462 patients for the TACE group and 627 for the TARE group. The median LC was 68.7% for TACE and 78.9% for TARE. The median OS was 15.3 months for TACE and 11.9 for TARE. Progression at three months was 32.5% for TACE and 20.6% for TARE. Conclusions: The included studies were heterogeneous, varying widely in design, patient selection, and therapeutic protocols. Nonetheless, this systematic review suggests that locoregional therapies are effective in the treatment of liver metastases in patients with breast cancer and may improve tumor burden, alleviate symptoms and extend overall survival. The median LC of the liver metastases at three months was higher in the TARE group compared to TACE. However, the TARE group showed lower OS rates after treatment.<\/jats:p>","DOI":"10.3390\/tomography11070081","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T10:46:05Z","timestamp":1752662765000},"page":"81","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TACE Versus TARE in the Treatment of Liver-Metastatic Breast Cancer: A Systematic Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1384-3703","authenticated-orcid":false,"given":"Charalampos","family":"Lalenis","sequence":"first","affiliation":[{"name":"Radiology Unit, Bolzano Hospital, Azienda Sanitaria dell\u2019Alto Adige, Via Lorenz B\u00f6hler 5, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-3413","authenticated-orcid":false,"given":"Alessandro","family":"Posa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-7051","authenticated-orcid":false,"given":"Valentina","family":"Lancellotta","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Lippi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marazzi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-7180","authenticated-orcid":false,"given":"Pierluigi","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-6352","authenticated-orcid":false,"given":"Patrizia","family":"Cornacchione","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias Joachim","family":"Fischer","sequence":"additional","affiliation":[{"name":"Radiology Unit, Merano Hospital, Azienda Sanitaria dell\u2019Alto Adige, Via G. Rossini 5, 39012 Merano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2791-481X","authenticated-orcid":false,"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiation Oncology, and Hematology, A. Gemelli University Hospital Foundation, IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy"},{"name":"Faculty of Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, Sede di Roma, Largo F. Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3322\/caac.21718","article-title":"Cancer statistics for African American\/Black People 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"e58846","article-title":"Intra-arterial Chemotherapy in Patients with Metastatic Breast Cancer: A Scoping Review","volume":"16","author":"Basra","year":"2024","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gong, Y., Liu, Y.R., Ji, P., Hu, X., and Shao, Z.M. (2017). Impact of molecular subtypes on metastatic breast cancer patients: A SEER population-based study. Sci. Rep., 7.","DOI":"10.1038\/srep45411"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zuo, Q., Park, N.H., Lee, J.K., and Madak Erdogan, Z. (2022). Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism. Nutrients, 14.","DOI":"10.3390\/nu14122376"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Galiandro, F., Agnes, S., Moschetta, G., Orlandi, A., Clarke, G., Bria, E., Franceschini, G., Treglia, G., and Giovinazzo, F. (2022). Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14071691"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2329454","DOI":"10.2214\/AJR.23.29454","article-title":"Locoregional Therapies for Primary and Metastatic Breast Cancer: AJR Expert Panel Narrative Review","volume":"222","author":"Deipolyi","year":"2024","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.4254\/wjh.v8.i18.770","article-title":"Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis","volume":"8","author":"Facciorusso","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/1049732312452938","article-title":"Beyond PICO: The SPIDER tool for qualitative evidence synthesis","volume":"22","author":"Cooke","year":"2012","journal-title":"Qual. Health Res."},{"key":"ref_11","first-page":"i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Moberg","year":"2016","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jvir.2017.06.022","article-title":"Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study","volume":"28","author":"Iezzi","year":"2017","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_13","first-page":"1539","article-title":"The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE)","volume":"91","author":"Leelawat","year":"2008","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jvir.2008.06.017","article-title":"Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors","volume":"19","author":"Virmani","year":"2008","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_15","first-page":"773","article-title":"Abscopal effect and interventional oncology: State of art and future perspectives","volume":"24","author":"Fionda","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.jvir.2015.08.027","article-title":"Management of High Hepatopulmonary Shunting in Patients Undergoing Hepatic Radioembolization","volume":"26","author":"Ward","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00270-005-0171-4","article-title":"Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): Assessment of hepatic arterial embolization","volume":"29","author":"Sato","year":"2006","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2008-1052306","article-title":"Radioembolization of yttrium-90 microspheres for hepatic malignancy","volume":"25","author":"Murthy","year":"2008","journal-title":"Semin. Interv. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00270-016-1310-9","article-title":"Radioembolization: Is Prophylactic Embolization of Hepaticoenteric Arteries Necessary? A Systematic Review","volume":"39","author":"Borggreve","year":"2016","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.RVI.0000116190.44877.04","article-title":"Chemoembolization of liver metastasis from breast carcinoma","volume":"15","author":"Giroux","year":"2004","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.3748\/wjg.v11.i24.3782","article-title":"Treatment for liver metastases from breast cancer: Results and prognostic factors","volume":"11","author":"Li","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00330-009-1525-0","article-title":"Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer","volume":"20","author":"Vogl","year":"2010","journal-title":"Eur. Radiol."},{"key":"ref_23","first-page":"251621","article-title":"Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases","volume":"2010","author":"Cho","year":"2010","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00432-011-1008-y","article-title":"Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: A retrospective analysis","volume":"137","author":"Duan","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1016\/j.ejrad.2013.08.046","article-title":"Transarterial chemoembolisation (TACE) with gemcitabine: Phase II study in patients with liver metastases of breast cancer","volume":"82","author":"Eichler","year":"2013","journal-title":"Eur. J. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00270-016-1465-4","article-title":"Doxorubicin-Loaded 70-150 \u03bcm Microspheres for Liver-Dominant Metastatic Breast Cancer: Results and Outcomes of a Pilot Study","volume":"40","author":"Lin","year":"2017","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10549-011-1926-z","article-title":"Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin","volume":"132","author":"Martin","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_28","first-page":"3063","article-title":"Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization","volume":"38","author":"Chang","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e28407","DOI":"10.1097\/MD.0000000000028407","article-title":"CalliSpheres drug-eluting beads transarterial-chemoembolization in the treatment of liver metastases from breast cancer: Initial experience in 14 patients","volume":"100","author":"Chang","year":"2021","journal-title":"Medicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12957-021-02332-0","article-title":"Clinical application of gelatin sponge microparticles combined with pirarubicin for hepatic transcatheter arterial chemoembolization in breast cancer liver metastasis treatment: Results of a single-center long-term study","volume":"19","author":"Zhao","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jvir.2007.02.019","article-title":"90Y radioembolization of metastatic breast cancer to the liver: Toxicity, imaging response, survival","volume":"18","author":"Bangash","year":"2007","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2007.03.056","article-title":"Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer","volume":"69","author":"Coldwell","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jvir.2008.01.009","article-title":"Radioembolization in patients with hepatic metastases from breast cancer","volume":"19","author":"Jakobs","year":"2008","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.115.165050","article-title":"Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients","volume":"57","author":"Fendler","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jvir.2016.05.028","article-title":"Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience","volume":"27","author":"Pieper","year":"2016","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","article-title":"Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)","volume":"44","author":"Helmberger","year":"2021","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Schatka, I., Tschernig, M., Rogasch, J.M.M., Bluemel, S., Graef, J., Furth, C., Sehouli, J., Blohmer, J.U., Gebauer, B., and Fehrenbach, U. (2021). Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. Cancers, 13.","DOI":"10.3390\/cancers13153777"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100838","DOI":"10.1016\/j.adro.2021.100838","article-title":"Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study","volume":"7","author":"Barakat","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jvir.2019.12.013","article-title":"Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer","volume":"31","author":"Davisson","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1245\/s10434-013-3436-1","article-title":"Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: A large single-center experience of 40 patients","volume":"21","author":"Saxena","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jvir.2014.07.007","article-title":"Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy","volume":"25","author":"Gordon","year":"2014","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00330-012-2556-5","article-title":"Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer","volume":"23","author":"Cianni","year":"2013","journal-title":"Eur. Radiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"109539","DOI":"10.1016\/j.ejrad.2021.109539","article-title":"Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer","volume":"136","author":"Ridouani","year":"2021","journal-title":"Eur. J. Radiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: Five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.5306\/wjco.v11.i10.761","article-title":"Colorectal liver metastases: Current management and future perspectives","volume":"11","author":"Martin","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_46","first-page":"78","article-title":"Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"26","author":"Baselga","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_47","first-page":"44","article-title":"Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial","volume":"15","author":"Porras","year":"2001","journal-title":"Oncology"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cheng, X., Li, J., Feng, L., Feng, S., Wu, X., and Li, Y. (2022). The role of hypoxia-related genes in TACE-refractory hepatocellular carcinoma: Exploration of prognosis, immunological characteristics and drug resistance based on onco-multi-OMICS approach. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1011033"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s00270-021-02906-1","article-title":"Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis","volume":"44","author":"Aarts","year":"2021","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_50","unstructured":"(2025, March 18). NCCN Guidelines. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"key":"ref_51","first-page":"192","article-title":"Can A Dedicated Multidisciplinary Tumor Board Improve Personalized Medicine for Patients in Interventional Oncology? A Large Retrospective Single-Center Experience","volume":"37","author":"Iezzi","year":"2022","journal-title":"Turk. J. Oncol."},{"key":"ref_52","first-page":"16","article-title":"Interventional oncology: Should interventional radiotherapy (brachytherapy) be integrated into modern treatment procedures","volume":"34","author":"Tagliaferri","year":"2019","journal-title":"Turk. J. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5114\/jcb.2018.76982","article-title":"ENT COBRA ONTOLOGY: The covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy)","volume":"10","author":"Tagliaferri","year":"2018","journal-title":"J. Contemp. Brachyther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5114\/jcb.2020.94579","article-title":"SKIN-COBRA (Consortium for Brachytherapy data Analysis) ontology: The first step towards interdisciplinary standardized data collection for personalized oncology in skin cancer","volume":"12","author":"Lancellotta","year":"2020","journal-title":"J. Contemp. Brachyther."}],"container-title":["Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2379-139X\/11\/7\/81\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:00Z","timestamp":1760033340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2379-139X\/11\/7\/81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["tomography11070081"],"URL":"https:\/\/doi.org\/10.3390\/tomography11070081","relation":{},"ISSN":["2379-139X"],"issn-type":[{"value":"2379-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]}}}